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Abstract
Attention deficit/hyperactivity disorder (ADHD) is one of the most common mental disorders in childhood and adolescence 
and is associated with functional, psychosocial and cognitive impairment. As part of the second wave of the German 
Health Interview and Examination Survey for Children and Adolescents (2014-2017), parents of children and adolescents 
aged between 3 and 17 years reported whether their child was diagnosed with ADHD by a physician or psychologist. 
Overall, 4.4% of children and adolescents have been diagnosed with ADHD in Germany. In comparison, the KiGGS 
baseline study (2003-2006) showed a reduction of lifetime ADHD diagnoses of almost one percentage point over a 
period of ten years. The reduction of parent-reported ADHD diagnoses primarily occurred among 3- to 8-year old children 
and boys. The results are discussed in terms of health promotion and the introduction of health care measures.
  MENTAL HEALTH · ADHD · PREVALENCE AND TIME TREND · HEALTH MONITORING · KIGGS
Introduction
Attention deficit/hyperactivity disorder (ADHD), with its 
three core symptoms of inattentiveness, hyperactivity 
(motor unrest) and impulsivity, is one of the most common 
mental disorders in childhood and adolescence [1-3]. ADHD 
is estimated to have a worldwide prevalence of approxi-
mately 5%; this has remained relatively stable over the last 
few decades [1, 4, 5].
According to the diagnostic criteria used by the classifica-
tion  systems (International Statistical Classification of Dis-
eases and Related Health Problems, 10th revision, ICD-10; 
Diagnostic and Statisti cal Manual of Mental Disorders, 5th 
Edition, DSM-5) and diagnostic guidelines (e.g. the ADHD 
working group of physicians in child and adolescent 
medicine [6]), a diagnosis of ADHD requires that core 
symptoms persist beyond developmentally inappropriate 
levels for at least six months, are pervasive across settings 
(e.g. school and home) and associated with substantial 
functional psychosocial impairment [7, 8]. Boys are diag-
nosed more frequently with ADHD than girls [9]. Approxi-
mately, 60% to 70% of patients with ADHD in childhood 
show a persistence of symptoms into adulthood [1, 10]. 
ADHD is commonly diagnosed among children of prima-
ry-school age [3] as symptoms become progressively more 
evident and cause greater impairment due to the increas-
ing external demands placed upon children in school 
(e.g. maintaining attention, remaining seated) [1].
Comorbidities are highly prevalent among children and 
adolescents with ADHD and vary between 60% and 80% 
depending on the study [11, 12]. The most common 
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as well as KiGGS Wave 2 cross-sectional study – participant 
acquisition, response rates and representativeness in issue 
1/2018 of the Journal of Health Monitoring [21, 22].
The lifetime prevalence of ADHD was assessed for chil-
dren and adolescents aged 3 to 17 years using parent-re-
ported ADHD diagnoses given by a physician or a psycholo-
gist (see [23]). The results for the current lifetime prevalence 
are based on data from 13,270 children and adolescents 
(6,671 girls, 6,599 boys) between 3 and 17 years of age from 
KiGGS Wave 2. Data from 13,487 children and adolescents 
(6,736 girls, 6,751 boys) from the KiGGS baseline study 
were used for comparison to analyse time trends. Preva-
lences of ADHD diagnoses are presented stratified by gen-
der, age and socioeconomic status (SES, [24]).
The analyses were carried out using a weighting factor 
that corrected for deviations within the sample from the 
population structure with regard to age in years, gender, 
federal state, German citizenship and the parents’ level of 
education [25]. Results report lifetime prevalences strati-
fied by gender, age, and SES with 95% confidence intervals 
(95% CI). The p-values calculated for the analysis of time 
trends are based on age-standardised prevalences (popu-
lation on 31 December 2015). Differences were examined 
using univariate logistic regression. A statistically signifi-
cant difference between groups is assumed to have been 
demonstrated where p-values are less than 0.05.
Results and discussion
Overall, 4.4% of children and adolescents between 3 and 17 
years of age showed a parent-reported lifetime diagnosis of 
ADHD given by a physician or psychologist for KiGGS 
Wave 2 (2014-2017) (Table 1). For the KiGGS baseline study, 
comorbid mental disorders are oppositional defiant disor-
der (ODD), conduct disorder (CD), depression, anxiety, 
and learning disabilities [7, 12]. Furthermore, the symptoms 
of ADHD among children and adolescents are associated 
with a reduced subjective health-related quality of life [13, 
14], increased accident-proneness [15], decreased educa-
tional attainment [16], increased disruption of family func-
tioning [17], conflict-ridden relationships with peers [16], 
and social stigmatisation [18]. Moreover, alongside the sig-
nificant functional impairment and the broad impact of 
ADHD on individuals and families, it is likely to incur a 
high level of health-care related costs [19, 20]. Consequently, 
it also has implications for health policy.
This study presents lifetime prevalences of parent-re-
ported ADHD diagnoses from the second wave of the Ger-
man Health Interview and Examination Survey for Children 
and Adolescents (KiGGS Wave 2, 2014-2017). Furthermore, 
it also describes time trends for a period of ten years by com-
paring data with the KiGGS baseline study (2003-2006).
Indicator 
The German Health Interview and Examination Survey for 
Children and Adolescents (KiGGS) is part of the health 
monitoring system established at the Robert Koch Institute. 
KiGGS includes repeated cross-sectional surveys of chil-
dren and adolescents aged between 0 and 17 years (KiGGS 
cross-sectional study). Both the KiGGS baseline study 
(2003-2006) and KiGGS Wave 2 (2014-2017) were conduct-
ed as a combined examination and interview survey. A 
detailed description of the methodology used in KiGGS 
Wave 2 can be found in New data for action. Data collec-
tion for KiGGS Wave 2 has been completed in issue S3/2017 
KiGGS Wave 2 
Second follow-up to the German Health 
Interview and Examination Survey for Children 
and Adolescents 
Data owner: Robert Koch Institute 
Aim: Providing reliable information on health 
status, health-related behaviour, living condi-
tions, protective and risk factors, and health 
care among children, adolescents and young 
adults living in Germany, with the possibility 
of trend and longitudinal analyses 
Study design: Combined cross-sectional and 
cohort study 
Cross-sectional study in KiGGS Wave 2
Age range: 0 -17 years
Population: Children and adolescents with 
permanent residence in Germany
Sampling: Samples from official residency 
registries - randomly selected children and  
adolescents from the 167 cities and municipal-
ities covered by the KiGGS baseline study
Sample size: 15,023 participants 
KiGGS cohort study in KiGGS Wave 2
Age range: 10 -31 years
Sampling: Re-invitation of everyone who took 
part in the KiGGS baseline study and who 
was willing to participate in a follow-up 
Sample size: 10,853 participants  
KiGGS survey waves
▶  KiGGS baseline study (2003-2006),  
examination and interview survey
▶  KiGGS Wave 1 (2009-2012),  
interview survey
▶  KiGGS Wave 2 (2014-2017),  
examination and interview survey
More information is available at 
www.kiggs-studie.de/english
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number of ADHD diagnoses among boys. No significant 
difference was observed for girls between both waves.
In comparison to the KiGGS baseline study, the results 
suggest that the diagnostic gap between girls and boys may 
be closing, however, the data show that boys are still diag-
nosed with ADHD twice as often as girls. Moreover, the 
time trend demonstrates that lifetime ADHD diagnoses 
significantly dropped among 3- to 5-year-olds and 6- to 
8-year-olds. No valid findings about gender specific differ-
ences within age groups can be made due to the small 
sample size within each group.
Children and adolescents living in socioeconomically 
disadvantaged families are more frequently diagnosed with 
ADHD compared to their peers from high SES families 
(Figure 1). Previous  results of the KiGGS baseline study and 
KiGGS Wave 1 confirm distinctive differences between the 
prevalence of ADHD diagnoses which are to the disadvan-
tage of lower SES households [3].
Over the last decade, a continuous increase in media 
reports and research, as well as the reported rise in the 
the prevalence of age-adjusted lifetime ADHD diagnoses 
was 5.3%. In contrast, a significant reduction in the preva-
lence of ADHD diagnoses of 0.9 percentage points (corre-
sponding to about 17 % compared to the baseline value) 
was identified from the data collected for KiGGS Wave 2. 
A gender comparison showed a significant reduction in the 
4.4% of children and  
adolescents between  
3 and 17 years of age had 
received a parent-reported  
lifetime diagnosis of ADHD 
from a physician or  
psychologist at KiGGS Wave 2 
(2014-2017).
Table 1 
Prevalences for parent-reported ADHD* 
diagnoses according to gender and age from 
the KiGGS baseline study 
(n=6,736 girls, n=6,751 boys) and 
KiGGS Wave 2 (n=6,671 girls, n=6,599 boys) 
Source: KiGGS baseline study (2003-2006), 
KiGGS Wave 2 (2014-2017)
* ADHD = Attention deficit/hyperactivity disorder
Figure  1 
Prevalences for parent-reported 
ADHD diagnoses* for 3- to 17-year-olds 
according to socioeconomic status 
(n=6,671 girls, n=6,599 boys) 
Source: KiGGS Wave 2 (2014-2017)
* ADHD = Attention deficit/hyperactivity disorder
KiGGS baseline study KiGGS Wave 2
% (95 % CI) % (95 % CI)
Girls 1.9 (1.5-2.4) 2.3 (1.9-2.8)
Boys 8.5 (7.7-9.5) 6.5 (5.7-7.3)
Age group
3-5 Years 1.5 (1.0-2.3) 0.2 (0.1-0.7)
6-8 Years 3.8 (3.1-4.7) 2.1 (1.5-2.9)
9-11 Years 7.6 (6.4-8.9) 6.1 (4.9-7.5)
12-14 Years 6.7 (5.6-7.9) 6.4 (5.3-7.6)
15-17 Years 6.4 (5.4-7.7) 6.9 (5.8-8.2)











Socioeconomic status: Low HighMedium
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for ADHD more often and earlier as their behaviour tends 
to be more disruptive (i.e. more hyperactive or impulsive) 
than girls [29]. A previous study found that ADHD is almost 
equally distributed between girls and boys when a higher 
level of diagnostic recognition is placed on the inattentive 
subtype and the less overt symptoms of ADHD which are 
more commonly found among girls [30].
Conclusions about the accuracy of ADHD diagnoses, 
whether these follow the guidelines, or the severity of the 
disorder cannot be drawn from the parent-reported ADHD 
diagnoses collected for the KiGGS study. Additionally, the 
question as to whether the parents’ response behaviour 
towards ADHD diagnoses might have been influenced by 
the changing public and professional perception over the 
last ten years remains open.
Overall, the study found a significant reduction in the 
diagnostic prevalence of about one percentage point over 
a period of ten years. Hence, it cannot be ruled out that 
this reduction might be a consequence of a more restric-
tive diagnostic practice for ADHD. This  explanation is cur-
rently supported by routine data gained from statutory 









diagnostic prevalence of ADHD, have driven a broad debate 
involving society, health policy, medical and psychological 
health care professionals, and service providers in the 
health system (see e.g. [26]).
This debate has resulted in the initiation of several meas-
ures related to health care policy and provision. One exam-
ple is the directive issued by the Federal Joint Committee 
(G-BA) for the modification of drug policies aimed at a 
more restrictive prescription of psychostimulants (i.e. 
methylphenidate) in the case of children and adolescents 
with ADHD [27]. The directive reflects the concern about 
the rate of prescriptions provided for stimulants as this 
increased over several years. Subsequently, medical guide-
lines for the diagnostics and therapy of ADHD have also 
been adapted (see [6]) and the Scientific Medical Societies 
in Germany (AWMF) has recently (June 2018) published a 
new version of its guidelines [28].
It cannot be ruled out that these changes may have led 
to the introduction of a more restrictive diagnostic practice 
in the case of ADHD. This assumption is supported by the 
recent reduction in the lifetime prevalence of ADHD among 
the youngest age groups, particularly as these were at the 
focus of the debate and have continued to be so. Other 
initiatives to promote children’s health at the federal level 
have also been introduced. These include the German gov-
ernment’s strategy for the promotion of children’s health, 
the promotion of the national centre for early support, 
which began in 2007, and the medical check-up (U10) put 
in place in 2006. However, the impact that they might have 
had on the prevalence of ADHD diagnoses remains open.
The results show that boys are still diagnosed twice as 
often with ADHD as girls. Boys are referred for treatment 
In contrast to the KiGGS 
baseline study (2003-2006), 
KiGGS Wave 2 showed a 
significant reduction in the 
prevalence of ADHD  
diagnoses of about one 
percentage point.
A reduction of parent- 
reported ADHD diagnoses 
was identified among boys 
and 3- to 8-year old children. 
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